ID   Hep-X1
AC   CVCL_C3MK
DR   CCRID; 4201PAT-CCTCC02164
DR   Wikidata; Q116049310
RX   PubMed=36152230;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2022181.
CC   Population: Chinese.
CC   Doubling time: ~60 hours (PubMed=36152230).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): PubMed=36152230
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D12S391: 18,22
ST   D13S317: 10
ST   D16S539: 12
ST   D18S51: 14,20
ST   D19S433: 13
ST   D21S11: 29,32.2
ST   D2S1338: 19,23
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D6S1043: 10,12
ST   D7S820: 11,12
ST   D8S1179: 15
ST   FGA: 21
ST   Penta D: 9
ST   Penta E: 15,17
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 05-10-23; Version: 4
//
RX   PubMed=36152230; DOI=10.1007/s13577-022-00797-z;
RA   Xu H., Miao X., Chai C.-P., Tang H., Hu J.-J., Zhao Z.-J., Luo W.,
RA   Zhu K.-X., Zhou W.-C.;
RT   "Establishment and characterization of a new Chinese hepatocellular
RT   carcinoma cell line, Hep-X1.";
RL   Hum. Cell 36:434-445(2023).
//